All Stories

  1. Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis
  2. Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis
  3. Combining Genetic Variants to Improve Risk Prediction for NAFLD and Its Progression to Cirrhosis: A Proof of Concept Study
  4. Lysosomal Acid Lipase Activity Is Reduced Both in Cryptogenic Cirrhosis and in Cirrhosis of Known Etiology
  5. The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients
  6. Breath-print analysis by e-nose for classifying and monitoring chronic liver disease: a proof-of-concept study
  7. Lysosomal acid lipase activity is reduced in patients with cirrhosis and associated with surrogate indices of portal hypertension
  8. Proton pump inhibitor prescription abuse and sepsis in cirrhosis
  9. Altered metal metabolism in patients with HCV-related cirrhosis and hepatic encephalopathy
  10. Portal inflammation during NAFLD is frequent and associated with the early phases of putative hepatic progenitor cell activation
  11. Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience
  12. Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens
  13. Determinants of alanine aminotransferase levels in a large population from Southern Italy: Relationship between alanine aminotransferase and age
  14. Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency
  15. 1539PLIVER TOXICITY IN COLORECTAL CANCER PATIENTS TREATED WITH FIRST LINE FOLFIRI-CONTAINING REGIMEN: A SINGLE INSTITUTION EXPERIENCE
  16. Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship
  17. Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination
  18. Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD
  19. Letter to the Editor Haemorrhoidal disease in severe portal hypertension: a combined approach with transjugular intrahepatic portosystemic shunt (TIPS) and transanal haemorrhoidal dearterialization (THD)
  20. Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis
  21. Prophylaxis of venous thromboembolism in elderly patients with multimorbidity
  22. Comparison of Disease Clusters in Two Elderly Populations Hospitalized in 2008 and 2010
  23. Cardiotrophin-1 is not associated with carotid or coronary disease and is inversely associated with obesity in patients undergoing coronary angiography
  24. Risk factors for hospital readmission of elderly patients
  25. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus
  26. HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
  27. Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma
  28. Hepatitis C in the elderly: A multicentre cross-sectional study by the Italian Association for the Study of the Liver
  29. Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients
  30. Toll-like receptor-4 expression by hepatic progenitor cells and biliary epithelial cells in HCV-related chronic liver disease
  31. Deep Vein Thrombosis, Inferior Vena Cava Interruption and Multiple Thrombophilic Gene Mutations
  32. Rapid virological response as a predictor of sustained response in HCV-infected patients with persistently normal alanine aminotransferase levels: A multicenter study
  33. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly
  34. The role ofS-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen
  35. Gas exchanges and pulmonary vascular abnormalities at different stages of chronic liver disease
  36. Angiogenic Cytokines in Patients Undergoing Antiviral Treatment for Chronic Hepatitis C Virus Infection
  37. The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen
  38. Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study
  39. Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma
  40. Non-cirrhotic portal hypertension with large regenerative nodules: A diagnostic challenge
  41. Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards
  42. In-hospital death according to dementia diagnosis in acutely ill elderly patients: the REPOSI study
  43. Gene therapy and enhancement for diabetes (and other diseases): the multiplicity of considerations
  44. Blood glucose monitoring in the normal population: the PREDICA study
  45. In-Hospital Death and Adverse Clinical Events in Elderly Patients According to Disease Clustering: The REPOSI Study
  46. Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial
  47. Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon α-2a and ribavirin: a multicentric study
  48. Interaction of alcohol intake and cofactors on the risk of cirrhosis
  49. A mocking finding: portal cavernoma mimicking neoplastic mass: first sign of myeloproliferative disorder in a patient with Janus kinase2 V617F mutation
  50. Association Between Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease: A First Message Should Pass
  51. Menarche in type 1 diabetes is still delayed despite good metabolic control
  52. Immune complexed (IC) hepatitis C virus (HCV) in chronically and acutely HCV-infected patients
  53. Pancreatitis after percutaneous ethanol injection into HCC: a minireview of the literature
  54. Westernization of the Filipino population resident in Rome: obesity, diabetes and hypertension
  55. The PTPN22 1858T Gene Variant in Type 1 Diabetes Is Associated With Reduced Residual  -Cell Function and Worse Metabolic Control
  56. 826 ANTIVIRAL TREATMENT OF HCV CARRIERS WITH NORMAL ALT
  57. Peripheral Graft Infection due to Staphylococcus aureus without Abnormal Findings by 99mTc-HMPAO-Labeled-Leukocyte Scan
  58. Percutaneous ultrasound-guided ablation of BW7756-hepatoma using ethanol or acetic acid in a rat model
  59. Lower schooling, higher hepatitis C virus prevalence in Italy: An association dependent on age
  60. Portal Diameter in the Diagnosis of Esophageal Varices in 266 Cirrhotic Patients: Which Role?
  61. Raised C-reactive protein levels in patients with recent onset type 1 diabetes
  62. Chemotherapy-Induced Steatohepatitis in Colorectal Cancer Patients
  63. Glucose Abnormalities in Patients With Hepatitis C Virus Infection: Epidemiology and Pathogenesis: Response to Lecube et al.
  64. Metabolic Factors Affecting Residual Beta Cell Function Assessed by C-Peptide Secretion in Patients with Newly Diagnosed Type 1 Diabetes
  65. Blood ketone bodies in patients with recent-onset type 1 diabetes (a multicenter study)
  66. Subcellular shift of the hepatic growth hormone receptor with progression of hepatitis C virus-related chronic liver disease
  67. Left common and right internal carotid artery occlusion - color-coded duplex sonography and magnetic resonance angiography findings
  68. Frequency of diabetes and thyroid autoantibodies in patients with autoimmune endocrine disease from Cameroon
  69. Associations between the IGF system and inflammatory markers in inflammatory bowel disease: authors' reply
  70. Diabetes in chronic liver disease: from old concepts to new evidence
  71. Vitamin D T1D
  72. Retroperitoneal Fibrosis and Ankylosing Spondylitis: Which Links?
  73. Isolated Hepatocytes versus Hepatocyte Spheroids: In Vitro Culture of Rat Hepatocytes
  74. Infliximab reverses growth hormone resistance associated with inflammatory bowel disease
  75. Endothelial dysfunction and activation as an expression of disease: role of prostacyclin analogs
  76. Iloprost: an adjunctive approach to chronic viral hepatitis treatment
  77. Treatment of Cryptosporidiosis in Immunocompromised Hosts
  78. Residual insulin secretion at diagnosis of type 1 diabetes is independently associated with both, age of onset and HLA genotype
  79. Anti-lactoferrin antibodies in systemic lupus erythematosus: isotypes and clinical correlates
  80. The Role of Ribavirin in the Combination Therapy of Hepatitis C Virus Infection
  81. Improved Hepatic Perfusion After Iloprost Infusion in Patients with HCV Chronic Infection: A Pilot Study with Possible Therapeutic Implications
  82. Guest Editorial
  83. The antineoplastic role of bisphosphonates: from basic research to clinical evidence
  84. TNF- α and Growth Hormone Resistance in Patients with Chronic Liver Disease
  85. Growth hormone-stimulated insulin-like factor-1 and acid labile subunit in chronic liver disease
  86. GH-resistance in different stages of chronic liver disease
  87. Hemodynamic effects of a prostacyclin analog (iloprost) on portal flow velocity and volume and visceral artery circulation in patients with lower limb arteriopathy
  88. Severe Liver Dysfunction After Raltitrexed Administration in an HCV-Positive Colorectal Cancer Patient
  89. Viral cirrhosis with chronic right heart failure and cardiac liver sclerosis: a hypothesis on the differentiation between the two diseases through pulsed Doppler sonography examination
  90. Development of a New Bioartificial Liver Using a Porcine Autologous Biomatrix as Hepatocyte Support
  91. Case Report: Liver Cirrhosis After Prolonged Therapy with IFN- α plus Interleukin-2 in a Metastatic Renal Cancer Long-Term Survivor
  92. Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment
  93. Low doses of insulin-like growth factor-I improve nitrogen retention and food efficiency in rats with early cirrhosis
  94. Percutaneous transhepatic stenting by wallstents of portal vein and bile duct stenoses caused by immunoblastic sarcoma in a liver transplantation
  95. Reversal of basal ganglia hyperintensity on T1-weighted images on MRI after successful orthotopic liver transplantation (OLT)
  96. Effectiveness of Aprotinin in Orthotopic Liver Transplantation
  97. Indirect pathway of liver glycogen synthesis in humans is predominant and independent of beta-adrenergic mechanisms
  98. Intravenous infusion of diarginylinsulin, an insulin analogue: Effects on glucose turnover and lipid levels in insulin-treated type II diabetic patients